- Business Wire•yesterday
Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Merck , known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 results 12 weeks after completion of therapy from C-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B , the company’s investigational triple-combination therapy in treatment-experienced patients with hepatitis C virus genotype ...
- Associated Press•2 days ago
Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.
- Business Wire•2 days ago
Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C
Merck , known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus infection who were administered ZEPATIER® in the U.S.
MRK : Summary for Merck & Company, Inc. (new) - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||61.87 - 62.63|
|52 Week Range||53.06 - 66.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||43.89|
|Dividend & Yield||1.88 (2.99%)|
|1y Target Est||N/A|